Single-Cell Sequence Technology Used to Reveal Heterogeneity of Secondary Hyperparathyroidism

NCT ID: NCT06130683

Last Updated: 2024-12-27

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Total Enrollment: 12 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-11-10
• Study Completion Date: 2025-07-31

Brief Summary

This project intends to select cases that meet the research requirements, take secondary hyperparathyroidism, primary hyperparathyroidism and normal human parathyroid tissue, a total of three groups, 4 cases in each group, through the method of single-cell transcription and sequencing, construct a map of human parathyroid function types, reveal the gene structure and gene expression status of cells, and visualize the expression characteristics, intercellular heterogeneity, and heterogeneity of cell subsets of secondary hyperparathyroid cells in a hierarchical manner, draw a single-cell map, and compare the differences between groups. To explore the pathogenesis of secondary hyperparathyroidism.

Secondary hyperparathyroidism, parathyroid tissue of primary hyperparathyroidism and normal parathyroid tissue obtained by accident were collected, frozen and preserved, frozen tissue thawed, single-cell suspension was prepared and each cell was specifically labeled by the Mozhuo Genomics system, after oil breaking, polymerase chain reaction amplification, reverse transcription to obtain complementary DNA, and a library of complementary DNA that passed quality inspection was constructed to obtain high-quality data of parathyroid cells. Cell Ranger, R Seurat package, and t-SNE dimensionality reduction diagram were used to reduce the dimensionality, cluster, and visualize the data.

In order to construct a single-cell atlas of parathyroid glands, investigators performed cluster analysis of similar cells according to the gene expression profile, and then visualized the data by t-SNE. According to the results of cell clustering, the specific and highly expressed genes in each cell cluster were identified. Cell populations were identified according to the expression of landmark genes, and the differences in cell types and proportions between groups were compared.

Conditions

Secondary Hyperparathyroidism

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: PROSPECTIVE

Study Groups

Secondary Hyperparathyroidism

Patients who were diagnosed as secondary hyperparathyroidism

Single-cell sequencing

Intervention Type: OTHER

Single-cell sequencing technology can reveal the gene structure and gene expression status of individual cells, reflecting the heterogeneity between cells.

Primary Hyperparathyroidism

Patients who were diagnosed as primary hyperparathyroidism

Single-cell sequencing

Intervention Type: OTHER

Single-cell sequencing technology can reveal the gene structure and gene expression status of individual cells, reflecting the heterogeneity between cells.

Normal group

Parathyroid tissue obtained incidentally during other neck surgeries, derived from people without parathyroid disease.

Single-cell sequencing

Intervention Type: OTHER

Single-cell sequencing technology can reveal the gene structure and gene expression status of individual cells, reflecting the heterogeneity between cells.

Interventions

Single-cell sequencing

Single-cell sequencing technology can reveal the gene structure and gene expression status of individual cells, reflecting the heterogeneity between cells.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Study participants with a diagnosis of secondary hyperparathyroidism who underwent surgical treatment
• Study participants with a diagnosis of primary hyperparathyroidism who underwent surgical treatment
• Study participants who have obtained informed consent

Exclusion Criteria

• Other non-secondary hyperparathyroidism conditions such as primary hyperparathyroidism were excluded at the time of inclusion of study participants with essential hyperparathyroidism.
• Other non-primary hyperparathyroid conditions such as secondary hyperparathyroidism were excluded at the time of inclusion of study participants with essential hyperparathyroidism.
• Refusal of informed consent.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

China-Japan Friendship Hospital

OTHER

Sponsor Role: lead

Responsible Party

Meng Yang

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Meng Yang

Role: PRINCIPAL_INVESTIGATOR

China-Japan Friendship Hospital

Locations

China and Japan Friendship Hospital

Beijing, , China

Countries

China

Other Identifiers

2023-NHLHCRF-YYPPLC-ZR-08

Identifier Type: -

Identifier Source: org_study_id